TABLE 38Subgroup analyses

ScenarioDescriptionTrtQALYCost (£)ICERPCE
20K30K
10Baseline HAQ 1.8 (BSRBR186) (base case 1.05)N2.09046,594NA0.5280.350
10A3.39773,207Ex dom0.0440.029
10E3.80479,43119,1560.3890.447
10I4.10193,04645,8980.0390.174
11Baseline PASI 12.5 (base case 7.5)N4.81066,811NA0.4310.274
11A6.25790,42216,3100.1150.057
11E6.66198,21419,3190.2940.269
11I7.012107,98827,7780.1600.400
7Baseline PASI 12.5, and continue after 3 months only if respond to both PsARC and PASI 75 (base-case PsARC only)N4.81066,811NA0.3990.246
7E5.31574,865Ex dom0.0300.039
7A5.79081,63715,1250.1740.073
7I6.717101,79621,7390.3970.642
8Baseline PASI 12.5, and continue after 3 months if respond to either PsARC or PASI 75N4.81066,811NA0.4350.278
8A6.44893,60116,3490.1700.076
8E6.66598,29321,6090.2080.177
8I7.187111,94026,1770.1870.469
21Baseline PASI 12.5, and annual inpatient treatment for uncontrolled psoriasis (base-case UVB)N4.810171,746NA0.1850.079
21A6.257183,1847,9010.1010.053
21I7.012191,21610,6360.7100.855
21E6.661197,741Dom0.0040.013
30Baseline PASI zero (base case 7.5)N5.71328,908NA0.4980.330
30A7.06456,792Ex dom0.0180.019
30E7.51262,20918,5120.4710.549
30I7.75277,70464,7440.0130.102

A, adalimumab; E, etanercept; I, infliximab; Dom, dominated; Ex dom, extended dominated; N, palliative care; NA, not available; Trt, treatment.

From: 4, Assessment of cost-effectiveness evidence

Cover of Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation
Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.10.
Rodgers M, Epstein D, Bojke L, et al.
Southampton (UK): NIHR Journals Library; 2011 Feb.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.